ClinicalTrials.Veeva

Menu

Perception, Awareness, and Acceptance of Human Papillomavirus Disease and Vaccine Among Parents of Boys Aged 9 to 18 Years

Ann & Robert H Lurie Children's Hospital of Chicago logo

Ann & Robert H Lurie Children's Hospital of Chicago

Status

Completed

Conditions

Human Papillomavirus (HPV)

Treatments

Other: Survey

Study type

Observational

Funder types

Other

Identifiers

NCT01197079
Merck IISP 37875

Details and patient eligibility

About

The objectives of this study are:

  1. to determine the degree of understanding and perceived risks for human papillomavirus (HPV) disease, to examine and assess attitudes for personal use of HPV vaccine and identify potential barriers to HPV vaccine access and utilization in a population of young men who have sex with men (MSM) (under 26 years of age)and in parents of boys aged 9 to 18 years
  2. to determine HPV vaccine acceptance and predictors of acceptance in a population of young MSM and in patients of boys ages 9 to 18 years
  3. to develop strategies to overcome potential barriers to vaccination and improve vaccine access and utilization via development of targeted educational initiatives.

Enrollment

500 patients

Sex

Male

Ages

9 to 26 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • MSM group - under age 26 years
  • Parent group - parent of boy(s) ages 9 to 18 years

Exclusion criteria

  • MSM group - previous receipt of HPV vaccine
  • Parent group - previous receipt of HPV vaccine by male child

Trial design

500 participants in 2 patient groups

Parents - Private Pediatric Offices
Description:
Parents of Boys aged 9 to 18 years from Private Pediatric Offices
Treatment:
Other: Survey
Parents - Public Health Clinics
Description:
Parents of Boys aged 9 to 18 years from Public Health Clinics

Trial contacts and locations

7

Loading...

Central trial contact

Melvin V Gerbie, MD; Tina Q Tan, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems